CryoLife (CRY) Granted CE Mark for HeRO Graft
Tweet
Share
E-mailGet Alerts CRY Hot Sheet
Join SI Premium – FREE
CryoLife, Inc. (NYSE: CRY) announced achievement of a CE (Conformite Europeenne) Mark for the HeRO (Hemodialysis Reliable Outflow) Graft system produced at the Company's new manufacturing facility in Atlanta. The HeRO Graft is a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous stenosis.
The first HeRO Graft clinical cases in Europe are expected to be performed in July 2013. The surgeons performing these initial cases will establish the first HeRO Graft training center in Europe, which will support the Company's controlled market introduction of the product during the second half of 2013, followed by a broader European launch in 2014. The Company estimates the European market opportunity for the HeRO Graft to be approximately $30 million.
The first HeRO Graft clinical cases in Europe are expected to be performed in July 2013. The surgeons performing these initial cases will establish the first HeRO Graft training center in Europe, which will support the Company's controlled market introduction of the product during the second half of 2013, followed by a broader European launch in 2014. The Company estimates the European market opportunity for the HeRO Graft to be approximately $30 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Gray Media closes $750M note offering to refinance higher-rate debt
- CoVolt Power files for proposed IPO
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
